Breakthrough Population-Based Study Highlights Alarming Rise in COPD Multimorbidity Costs

Singapore's academic researchers have unveiled a pivotal population-based study shedding light on the escalating healthcare costs associated with Chronic Obstructive Pulmonary Disease (COPD) multimorbidity. Led by experts from the Saw Swee Hock School of Public Health at the National University of Singapore (NUS), in collaboration with Nanyang Technological University (NTU) and Duke-NUS Medical School, the research analyzes eight years of national health data to reveal patterns that demand urgent attention in this rapidly aging nation.

COPD, a progressive lung condition characterized by persistent respiratory symptoms and airflow limitation due to airway and alveolar abnormalities, often coexists with other chronic illnesses—a phenomenon known as multimorbidity. In multi-ethnic Singapore, where chronic respiratory diseases contribute 4.4% to the total disease burden, this study provides critical evidence for policymakers and clinicians alike.

Understanding COPD and Multimorbidity in the Singapore Context

Chronic Obstructive Pulmonary Disease (COPD) encompasses emphysema and chronic bronchitis, primarily caused by long-term exposure to irritants like cigarette smoke, air pollution, and biomass fuel. Unlike asthma, which is largely reversible, COPD involves irreversible damage, leading to breathlessness, cough, and frequent exacerbations. Multimorbidity refers to the coexistence of two or more chronic conditions, amplifying disease complexity, treatment burdens, and healthcare utilization.

In Singapore, COPD prevalence hovers around 6%, ranking it among the top 10 causes of death, with chronic obstructive lung diseases accounting for 1.2% of total deaths in 2023. Unique Asian factors, such as post-tuberculosis lung scarring and higher diabetes rates, exacerbate multimorbidity. The nation's aging population—one of the fastest globally, with 1 in 4 citizens aged 65+ by 2030—intensifies the burden, projecting COPD costs to SGD 6,500 per patient-year by 2025.

Methodology: Leveraging National Administrative Data for Robust Insights

The study utilized comprehensive claims data from Singapore's Ministry of Health, covering subsidized public healthcare from 2012 to 2019. Researchers identified 18,866 COPD patients (ICD-10 J40-J44, excluding asthma-COPD overlap) and propensity score-matched them 1:1 to non-COPD controls based on age, sex, ethnicity, socioeconomic status, and residency. Costs were annualized per patient-year (PY), adjusted to 2023 SGD, encompassing hospitalizations, primary/specialist care, emergency visits, and medications.

This real-world, population-based approach ensures generalizability, capturing 80% of Singapore's healthcare utilization while highlighting multimorbidity via comorbidity categorizations like circulatory, metabolic, and respiratory diseases.

Staggering Cost Figures: COPD Patients Bear Fivefold Burden

COPD patients incurred average annual direct medical costs of SGD 5,290.9 per PY—nearly five times higher than non-COPD peers at SGD 1,110.4 per PY. Of this, 33.8% (SGD 1,785.7) was directly COPD-attributable, with multimorbidity driving the rest.

Top multimorbidity drivers: other respiratory diseases (15.0%, SGD 793.7), circulatory (14.9%, SGD 788.1), metabolic (7.8%, SGD 412.7), digestive (4.7%, SGD 250.8).

Photo by Edwin Petrus on Unsplash

Temporal Trends: Shifting Cost Landscape 2012-2019

Total COPD costs rose 15.3% (SGD 745.4/PY), bucking hospitalization declines (-11.9%). Primary care surged 287.1% (SGD 1,190.4/PY), signaling increased chronic management needs. Mortality climbed from 7.1% to 11.1% in COPD cohorts.

• Primary care boom: Reflects preventive shifts under Healthier SG.
• Hospital decline: Possible better outpatient control.
• Mortality rise: Aging, multimorbidity interplay.

These trends underscore evolving care dynamics amid population aging.View full study

High-Cost Users: Profiles and Risk Factors

The top 10% (n=2,299) consumed 42.3% of costs (SGD 10,247.9/PY), characterized by older age (67.7 years), Indian ethnicity (67.2%), frequent hospitalizations (≥2/year), and elevated comorbidities: infectious (30.2%), neoplasms (15.7%), diabetes (25.8%), pneumonia (45.0%). Bottom 50%: younger Chinese-majority, lower utilization.

• Infectious diseases: Post-TB sequelae common in Asians.
• Neoplasms: Smoking history link.
• Ethnic disparities: Indians face higher burdens, possibly socioeconomic or genetic factors.

Targeting these profiles could optimize resource allocation.

University-Led Innovations Driving Change

NUS's Saw Swee Hock School of Public Health spearheaded analysis, partnering NTU's Lee Kong Chian School of Medicine and Duke-NUS. This aligns with TARIPH, NTU-led $10M initiative involving NUS, SGH, NUH for Asian-centric lung research, focusing COPD multimorbidity, early detection.TARIPH overview

Such collaborations position Singapore universities as respiratory health leaders, fostering translational research amid rising burdens.

Government Responses and Integrated Care Pathways

Singapore's Healthier SG emphasizes preventive, GP-centered care, aligning with study's primary care surge. COPD clinics at SGH, NTUH integrate multidisciplinary teams, pulmonary rehab, telehealth. TARIPH's weather-forecasting (FOCALS) prevents exacerbations.

Photo by Albert Vincent Wu on Unsplash

• Healthier SG: Enrollees get subsidized screenings, chronic plans.
• COPD-ICP: Reduces readmissions via home care.
• National efforts: Anti-smoking, pollution controls.

Future Outlook: Projections and Actionable Solutions

With aging demographics, COPD multimorbidity costs may exceed SGD 6,500/PY soon. Solutions: AI-driven risk stratification, personalized therapies, ethnic-tailored interventions. Universities like NUS/NTU lead via TARIPH till 2029, projecting integrated models reducing hospitalizations 20-30%.

Stakeholders: Policymakers prioritize funding; clinicians adopt multimorbidity screening; patients embrace lifestyle changes.

Careers in Respiratory Research and Public Health

This study exemplifies opportunities in Singapore's thriving academic health scene. Pursue research jobs at NUS/NTU or clinical roles via higher ed jobs. Explore career advice for public health paths. Check Rate My Professor for insights on faculty like those in TARIPH.

Interested in lecturing? View lecturer jobs in medicine.